Sabrina Serani

In an interview, Rawan Faramand, MD, discussed her research on cost-effectiveness of graft modification to prevent GVHD in hematopoietic cell transplant.

FDA fast track status was supported by two monotherapy responses in MSI-H colorectal cancer, including one complete response and one partial response, both durable beyond 80 weeks.

Targeted Oncology connects oncology professionals with updates on immunotherapy, biomarkers, cancer pathways, and targeted precision medicine strategies.

Izalontamab brengitecan achieved dual primary end point improvements in PFS and OS versus physician’s choice chemotherapy in previously treated locally advanced/metastatic TNBC, challenging later-line single-agent chemotherapy standards.

FDA clears HARMONIC trial changes as LP-300 targets EGFR L858R lung cancer after TKI failure, aiming for longer dosing and lower toxicity.

Hafnium oxide nanoparticle radioenhancer adds safely to standard chemoradiotherapy in unresectable stage III NSCLC, showing deep responses and promising early efficacy.

FDA extends camizestrant review as ctDNA-guided ESR1 switch sparks debate; new analyses debut at ASCO while Europe advances approval.

Data from the PANKU-Breast02 trial may support iza-bren as a new standard of care in this TNBC population.

Data from the VIKTORIA-1 trial support the PAM pathway as a molecular driver in HR-positive, HER2-negative breast cancer of any PIK3CA mutation status.

"The VIKTORIA-1 trial validates the PAM pathway as a molecular driver in hormone receptor–positive, HER2-negative advanced breast cancer, regardless of PIK3CA mutation status," said Sara Hurvitz, MD.